Newsletters


Filter by volume

Agenus on Twitter

$AGEN's #CTLA4 zali is active in #PD1 failures as shown in a study in #raretumors presented at #SITC2020. Out of 28 evaluable patients: DCR of 51.9%; 1 CR, 2 PRs. We have launched a Ph2 trial of bali + zali w SOC in #softtissuesarcoma w @breelynwilkyMD agenusbio.com/wp-content/upl…

What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle? Thanks to #IO360 you can hear from $AGEN President & COO @jbuell01, Dr. Chuck Drake and others describe what's needed - like our AGEN1181 a next gen CTLA-4 molecule. theconferenceforum.org/immuno-oncolog…

test Twitter Media - What Do Next Generation of Immunotherapies Need to Look Like to Move the Needle?  Thanks to #IO360 you can hear from $AGEN President & COO @jbuell01, Dr. Chuck Drake and others describe what's needed - like our AGEN1181 a next gen CTLA-4 molecule.  https://t.co/OJfDpoA3x9 https://t.co/HsW6L3mef3

$AGEN VISION platform studies cancer cell interactions in simulated tumor microenvironment to predict how immunotherapies will perform in patients & discover optimal combos. VISION outperforms standard IHC testing in predicting response to #PD1 therapy agenusbio.com/wp-content/upl…

Read more about our 7 presentations at #SITC2020 in our most recent newsletter: agenusbio.com/wp-content/upl…

AGEN2373, $AGEN's #CD137, demonstrated stable disease in 4 patients with advanced solid tumors and no liver toxicity up to 1mg/kg at #SITC2020. It also promotes intratumoral #Treg depletion

$AGEN's #TIGIT molecules are Fc-enhanced. Our #SITC2020 presentation shows this is important for superior tumor control and optimized performance compared to clinical-stage TIGITs and could broaden benefit to an additional 40% of #patients agenusbio.com/wp-content/upl…

$AGEN's goal is to bring treatments to cancer patients with #innovation and speed. We are excited to announce that Agenus is being recognized with a spot on @DeloitteTMT's 2020 Technology #Fast500 list, which celebrates innovative industry disruptors www2.deloitte.com/us/en/pages/te…

$AGEN latest newsletter is now available. Perspectives on Seven Agenus Programs Presented at SITC: agenusbio.com/wp-content/upl… Read about the programs and data Agenus presented on at #SITC2020 and their context within Agenus' broader pipeline and strategy #oncology

Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference investor.agenusbio.com/news-releases/…

Agenus and Dr. Steven O’Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data bit.ly/32HxtXi

$AGEN presents on 7 novel programs at #SITC2020 including our Fc-enhanced #TIGIT and our #AI R&D VISION platform. See highlights below! Click to view full posters: bit.ly/3eNEUkz

Meet our #SITC2020 presenters! Dr. Cesar Perez is a principal investigator for the Ph1/2 trial of zalifrelimab at the @SylvesterCancer where he is also the Head and Neck Oncology Lead #Immunotherapy #oncology #antiCTLA4

Meet our #SITC2020 presenters! As a senior scientist at $AGEN, Dr. Simarjot Pabla @PablaSimarjot is working on Agenus’ VISION platform. He is focused on using #artificialintelligence and machine learning to identify optimal treatment combinations for patients #immunotherapy

An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2 bit.ly/2UcyD8r

Meet our #SITC2020 presenters! Dr. Claire Galand @ClaireGaland is the senior scientist for the #pharmacology team at $AGEN. She currently leads the preclinical research for AGEN2373, our anti-CD137 #Immunotherapy #oncology

$AGEN President & COO Dr. @jbuell01 reports that iNKTs are a unique cell type that combines both arms of immunity, adaptive and innate, making them invaluable in combatting diseases like #cancer & #COVID19. Trial is underway @WeillCornell #CellTherapy twitter.com/jbuell01/statu…

Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020 investor.agenusbio.com/news-releases/…

Welcome Dr. @joegrossman7, our clinical expert advancing innovative early clinical trials for optimal combinations for patients with #cancer! #Biology #Immunotherapy twitter.com/jbuell01/statu…

Could #celltherapy be the answer to #COVID19? @DrMhidalgo, the Chief of Hematology and Oncology at @WeillCornell, speaks about iNKT cell therapy for COVID-19 and cancer. Read more here: boston.cbslocal.com/2020/11/02/cov… #FightCOVID19 #immunesystem @Agentus_CellTX investor.agenusbio.com/news-releases/…